

1 Personal view

2

3 **Bayesian versus frequentist methods for estimating disease true prevalence and**
4 **diagnostic test performance**

5

6

7 Moussa Sanogo ^{a,b,c}, Emmanuel Abatih ^b, Claude Saegerman ^{c,*}

8

9 ^a LANADA/Central Veterinary Laboratory of Bingerville, P.O. Box 206 Bingerville, Ivory
10 Coast

11 ^b Unit of Epidemiology and Biostatistics, Department of Biomedical Sciences, Institute of
12 Tropical Medicine (ITM), Nationalestraat, 155, B-2000, Antwerp, Belgium

13 ^c Research Unit of Epidemiology and Risk Analysis applied to Veterinary Sciences (UREAR-
14 ULg), Fundamental and Applied Research for Animals & Health, Faculty of Veterinary
15 Medicine, University of Liege (ULg), Boulevard de Colonster 20, B42, B-4000 Liege, Belgium

16

17

18

19

20 * Corresponding author. Tel.: +32 4 3664579.

21 Email address: claude.saegerman@ulg.ac.be (C. Saegerman).

22 **Introduction**

23 As the two main schools of statistical reasoning through which inference to the
24 population is made by analysing data and incorporating uncertainty of measures, Bayesian
25 and Frequentist philosophies have been used for estimation of diagnostic test performance and
26 the true prevalence of diseases. However, some controversies exist in this estimation between
27 these two philosophies like (e.g.) the use of fixed parameters values in frequentist approach or
28 the inclusion of prior information in Bayesian approach. Is the philosophical debate between
29 these two approaches still relevant for such practical questions?

30

31 The Bayesian philosophy arose from a statement made by the Reverend Thomas
32 Bayes (1702-1761), a British mathematician and theologian, who was the first to apply
33 statistical probability inductively. According to Bayes, '*all forms of inference are based on*
34 *the validity of their premises*' and that '*no inference can be known with certainty*' (Thrusfield,
35 2005). In 1814, the French mathematician, Simon-Pierre Laplace published a mathematical
36 description based on idea of Bayes (Gelman et al., 2004). In the Bayesian philosophy,
37 scientific observations do not exist in a vacuum and information available prior to making a
38 series of observations influences the interpretation of those observations (Thrusfield, 2005).

39

40 Bayesian analysis can be regarded as a process of adjusting and updating the
41 likelihood of an event based on data. Thus, population parameters, such as sensitivity (Se) and
42 specificity (Sp) are assumed to have a probability distribution representing our prior
43 knowledge of their values. This information is combined with observed factual field data in a
44 model for estimation (Speybroeck et al., 2012a). For Bayesians, a parameter is assumed to
45 have an intrinsic probability distribution with a 95% credibility interval (Gardner, 2002).
46 Thus, Bayesian principles often are applied to estimate disease prevalence and test

47 characteristics, especially when there is no gold standard, in veterinary or human health (Enøe
48 et al., 2000; Branscum et al., 2005; Rutjes et al., 2007; Meyer et al., 2009).

49

50 The frequentist philosophy emerged in the 20th century with the works of Fisher
51 (1922) and Neyman and Pearson (1928), who enunciated the concept of relative frequency
52 (Vallverdu, 2008). This concept sustains the idea that a probability is a frequency determined
53 from an experiment repeated a large number of times. Frequentist statisticians attempt to draw
54 conclusions by focussing primarily on results obtained from experiments or samples. In the
55 frequentist reasoning, a parameter is a fixed value with a 95% confidence interval derived
56 from the sample. It is assumed that this 95% confidence interval would contain the true value
57 of the parameter 95% of the time if estimation were repeated a large number of times.

58

59 Therefore, Bayesian philosophical methods are based on the idea that unknown
60 quantities, such as population means or proportions, have a probability distribution that
61 expresses our prior knowledge or belief about such quantities, before we add the knowledge
62 gained from observational data. Bayesian inference considers the data to be fixed and
63 parameters to be random, because they are unknown. In frequentist methods, prior knowledge
64 is apprehended differently and population means or proportions are considered as fixed values
65 (Bland and Atlman, 2002). Frequentist inference considers the unknown parameters to be
66 fixed and the data to be random.

67

68 Both Bayesian and frequentist methods have been published to handle a variety of
69 situations in which diagnostic tests are evaluated. In this personal view, we comment on
70 requirements, limitations and controversial points of proposed methods for estimating test
71 performance and the true prevalence of disease, through the case where one test or a

72 combination of two imperfect diagnostic tests is used in the absence of an appropriate gold
73 standard.

74

75 **Estimating the true prevalence of disease and diagnostic test performance with**
76 **imperfect tests**

77 The ability of a diagnostic test to correctly distinguish truly diseased from non-
78 diseased individuals when applied to a randomly chosen population is required to
79 understanding the epidemiology of the disease, to implement disease control programmes and
80 to evaluate new diagnostic tests (Greiner and Gardner, 2000; Lewis and Torgerson, 2012).
81 Mathematically, estimation of test performance parameters is essentially the same question as
82 estimating true prevalence (Lewis and Torgerson, 2012). The true prevalence (the proportion
83 of truly diseased individuals in the population of interest) is also an essential parameter to
84 appraise the impact of a disease in a population of interest and to prevent biased estimation of
85 disease burden (Dohoo et al, 2003; Speybroeck et al., 2012a).

86

87 The accuracy of estimation of true prevalence depends on the performance parameters
88 of the test(s) to be applied (Ihorst et al., 2007). Among performance indicators of a diagnostic
89 test, Se and Sp are the most commonly used. Test Se (or Sp) indicates the probability that a
90 truly infected (or non-infected) individual yields a positive (or a negative) test result. Ideally,
91 Se and Sp values for a given test should be estimated from a reference population with a
92 clearly identified status determined by historical (accurate) information or, more commonly,
93 by a relevant gold standard ($Se = 1$ and $Sp = 1$), which is able to discriminate
94 infected/diseased individuals from non-infected/non-diseased individuals in a population
95 (Dohoo et al., 2003). When such a perfect test exists, estimation of performance parameters of
96 the new test, as well as true prevalence, can be done easily (Rogan and Gladen, 1978).

97

98 In practice, such a test is hardly ever available, given that the diagnostic performance

99 of a test is influenced by a number of endogenous and exogenous factors (Rutjes et al., 2007).

100 As an alternative, a combination of multiple imperfect tests ($Se < 1$ and/or $Sp < 1$) may be used

101 for estimation of disease parameters (Black and Graig, 2002). With multiple tests, the overall

102 misclassification errors are reduced and are expected to be lower than with a single imperfect

103 test.

104

105 As an example, isolation and identification of *Brucella* spp is considered as the

106 reference standard method, and a positive test result provides an unequivocal diagnosis of a

107 positive brucellosis case (OIE, 2009). However, these methods are not always feasible in

108 diagnostic investigations. Therefore, diagnosis must be based on imperfect serological

109 methods, such as the Rose Bengal test (RBT) and the indirect ELISA (iELISA), which are the

110 two OIE proscribed tests for trade and are commonly used in combination for the diagnosis of

111 brucellosis (Nielsen, 2000; Saegerman et al., 2004; OIE, 2009; Godfroid et al., 2010; Sanogo

112 et al., 2013).

113

114 Estimation of true disease prevalence and test characteristics with combined imperfect

115 tests implies to deal with various challenges including (1) potential misclassification errors,

116 (2) possible dependence between tests and (3) sparseness of data (Cowling et al., 1999;

117 Dohoo, et al., 2003; Messam et al., 2008). Both Bayesian and frequentist approaches have

118 been proposed to tackle these challenges.

119

120 **Estimation with a single test**

121 In the simple case where a single imperfect diagnostic test is applied in a population of
122 interest, a total of three parameters have to be estimated, whatever the method: Se, Sp and true
123 prevalence. In this case, the apparent prevalence (the proportion of positive test results) is the
124 only information given by the data. From a frequentist perspective, estimation can be done
125 only if fixed external information is provided on the values of Se and Sp, but this is difficult,
126 since test properties are known to be context-specific and cannot be realistically assumed to
127 be fixed and known in advance (Thrusfield, 1995), for example, the given values by the
128 manufacturer of a test.

129

130 As far as external information has to be included for estimation, Bayesian methods
131 seem to be more helpful in obtaining acceptable and realistic results, since they offer the
132 possibility to include the known uncertainty on diagnostic test characteristics while testing
133 whether data conflict with prior information (Joseph et al., 1995; Berkvens et al. 2006;
134 Speybroeck et al., 2012b). However, the accuracy of Bayesian estimates is dependent on the
135 availability and the quality of prior knowledge, which may be a limiting factor and also
136 constitute a source of controversy with frequentist philosophy.

137

138 **Estimation with a more than a single test**

139 When a combination of at least two tests is used, the test results for a given individual
140 could be interpreted either in series (only animals testing positive to both tests are considered
141 to be test positive) or in parallel (animals that tested positive to one test, to the other test or to
142 both tests are considered to be test positive) (Black and Graig, 2002). A combination of tests
143 may also result in dependence or correlation between the test results. As a consequence, either
144 conditional independence or conditional dependence assumptions need to be made for
145 accurate estimation of disease prevalence and test properties (Jones et al., 2010).

146

147 Conditional independence implies that the results of the second test (T2) do not
148 depend on whether the results of the first test (T1) are positive or negative among infected (or
149 non-infected) individuals (Gardner et al., 2000; Enøe et al, 2000). If we consider the skin test
150 or the iELISA, two tests for the diagnosis of brucellosis, conditional independence is likely to
151 exist considering their respective targets (cellular response for the skin test and humoral
152 response for iELISA), especially in a low prevalence context (Saegerman et al., 1999). In this
153 case, calculation of test Se and Sp will depend mainly on the testing strategy (in parallel or in
154 series) adopted (Dohoo et al., 2003).

155

156 Mathematically, assumptions such as conditional independence and a constant
157 prevalence over sub-populations, are needed to estimate the prevalence (Enøe et al., 2000).
158 These assumptions are necessary to reduce the number of unknown parameters to be
159 estimated (Berkvens et al., 2006). Gart and Buck (1966) and Staquet et al. (1981) proposed
160 frequentist methods assuming conditional independence between a new test and a reference
161 test with known Se and/or Sp. However, test Se (stage of infection) and Sp (similar
162 immunogenic component) values are known to be under the influence of the characteristics of
163 the population in which the test is applied (Saegerman et al., 2004; Berkvens et al., 2006) and
164 cannot be considered as intrinsic constant and known parameters (Thrusfield, 1995).
165 Moreover, assuming fixed values might not be realistic, since many factors, such as the
166 presence of cross-reacting agents (Saegerman et al., 2004) and low infection pressure, may
167 influence test parameter values (Speybroeck et al., 2012b).

168

169 Another major frequentist method was proposed by Hui and Walter (1980) to deal
170 with the case where Se and Sp values of the reference test are unknown. In addition to

171 conditional independence assumption, this latter approach required testing results from at
172 least two populations with distinct prevalences of disease, but constant Se and Sp (Hui and
173 Zhou, 1998; Enøe et al., 2000; Dohoo et al., 2003). This approach was extended to cover
174 other settings, including cases with more than two tests and multiple populations (Walter and
175 Irwig, 1988; Johnson et al., 2001). Accuracy of estimates with these methods also relies on
176 the assumption of a large sample size (Enøe et al., 2000; Pouillot et al., 2002; Berkvens et al.,
177 2003; Pouillot, 2003). Toft et al. (2005) provide a useful overview of possible pitfalls when
178 using this paradigm, especially the conditional independence assumption, which is not always
179 satisfied in practice (Gardner et al., 2000; Dendukuri and Joseph, 2001; Branscum et al.,
180 2005; Berkvens et al, 2006).

181

182 Testing situations handled by the frequentist models of Gart and Buck (1966) and the
183 case of unknown Se and Sp already covered by the model of Hui and Walter (1980) were also
184 examined under the Bayesian framework. Joseph et al. (1995) proposed a Bayesian model for
185 estimation with no constrained parameters and assuming conditional independence.
186 Numerically, this model appeared to be approximately equivalent to the frequentist approach
187 (Dendukuri and Joseph, 2001). Nevertheless, even if estimation was possible with this latter
188 model, inclusion of information on the uncertainty of parameters to be determined is required
189 to get realistic and meaningful estimates (Enøe et al., 2000).

190

191 Conditional dependence particularly occurs when combined tests target a similar
192 biological phenomenon, such as presence of immunoglobulins (Igs) (Gardner et al., 2000;
193 Dendukuri and Joseph, 2001). Thus, conditional dependence is likely to exist between the
194 RBT and iELISA, two assays targeting the similar anti-*Brucella* antibodies. In fact, RBT
195 detects the presence of IgG₁ (IgG₂ and IgM also have some agglutination activity), while the

196 iELISA targets IgG₁ and/or IgG₂, depending on the conjugate used (Nielsen, 2002;
197 Saegerman et al., 2004 and 2010; Sanogo et al., 2013). In this scenario, calculation of test Se
198 and Sp under conditional independence is adjusted with the inclusion of the covariance factor
199 expressing the extent of the dependence among positive and negative results, and by taking
200 the testing strategy into account (Dohoo et al., 2003).

201

202 When dependence is present, adjustment of estimations should be done by considering
203 biological and technical mechanisms giving rise to the test results and by including the extent
204 of the dependence between them (Pepe and Janes, 2007). With two correlated tests, a total of
205 seven parameters have to be estimated instead of five under conditional independence (e.g.
206 two sensitivities, two specificities, two covariances and the true prevalence) and the
207 dependence needs to be accounted for (Berkvens et al., 2006; Praet et al., 2006). Some
208 frequentist methods require the application of at least two tests to allow estimation of
209 parameters of interest (Dendukuri and Joseph, 2001). Such an approach might be impractical,
210 when tests are expensive, time consuming or invasive.

211

212 Instead of using results from at least two tests to allow estimation of disease
213 parameters, Bayesian modelling offers an alternative option to get the estimates of the true
214 prevalence of disease and test Se and Sp, while accounting for conditional dependence (Qu
215 and Hagdu, 1998; Gardner et al., 2000; Dendukuri and Joseph, 2001; Georgiadis et al., 2003;
216 Sanogo et al., 2013). However, informative priors are needed for at least four of the
217 parameters of the model, which are two sensitivities, two specificities, two covariances and
218 the true prevalence.

219

220 **Bayesians *versus* frequentist methods**

221 Previously difficult to apply because of major mathematical and computational
222 requirements, application of Bayesian approaches was facilitated by the Markov Chain Monte
223 Carlo (MCMC) methods and the availability of high quality statistical software packages
224 including JAGS (Plummer, 2003), WinBUGS (Lunn et al., 2000) and OpenBUGS (Lunn et
225 al., 2009). These approaches are now the tools of choice in many areas of application and
226 appear to offer some practical advantages over their frequentist counterparts (Greiner and
227 Gardner, 2000; Dunson, 2001; O'Hagan, 2004).

228

229 By giving the possibility to combine additional knowledge and the likelihood of
230 parameters in the population of interest in the same model, estimation is facilitated in
231 Bayesian methods. Thus, uncertainty on Se and/or Sp of the reference test, expressed as
232 probability distributions, are combined with factual observed field data to produce posterior
233 probability distributions of true prevalence and test performance (Speybroeck et al, 2012b).
234 Compared to frequentist methods, Bayesian methods also seem to offer more options and
235 flexibility to get the best possible estimates of parameters in various realistic settings.
236 Especially, the presence of conditional dependence when two imperfect tests are used can be
237 addressed in a Bayesian framework by running both models with conditional independence
238 between tests given true disease status and those with conditional dependence and checking
239 the robustness of parameters or using model selection criteria such as the Deviance
240 Information Criterion (DIC) (Berkvens et al., 2006; Dendukuri et al., 2010). Robustness of
241 estimates should also be systematically checked across a range of plausible values based on
242 the evidence to date (Enøe et al., 2000, Speybroeck et al., 2012a).

243

244 A systematic review and/or quantitative reviews summarising data using appropriate
245 meta-analytic methodologies should be particularly preferred to get informative priors on

246 diagnostic test performance (Irwig et al., 1995; Dohoo et al., 2003, EFSA, 2009). In any case,
247 application of evidence-based medicine and the quality assurance of the process to get prior
248 information are important to assess the quality of the approach. In the case of emerging
249 infectious diseases, where prior information may not be available yet and constitutes a
250 limiting factor, non-informative priors might be used. When no informative prior knowledge
251 is included in the estimation process, results of frequentist and Bayesian analysis are
252 extremely similar (Enøe et al., 2000; Dendukuri and Joseph, 2001). Whatever the priors, a
253 sensitivity analysis of prior information should be undertaken to assess its potential influence
254 on estimates (Menten et al., 2008; Sanogo et al., 2013). Thus special care should be given to
255 the selection of available information in order to get unbiased estimates (Spiegelhalter et al.,
256 2002; Berkvens et al., 2006). The procedure for incorporating available knowledge or the
257 prior information into the model and the mathematical issues have been described previously
258 (Enøe et al., 2000; Gardner et al., 2000; Dendukuri and Joseph, 2001; Branscum et al., 2005;
259 Berkvens et al. 2006).

260

261 Besides the challenges related to misclassification bias, the representativeness of data
262 regarding the population of interest and the quality assurance of the process (traceability) are
263 two key issues to be considered in both approaches. Thus, different stages of the disease and
264 age of animals should be considered and an appropriate sampling strategy should be used to
265 compose the reference population and consequently minimise sampling error and biased
266 posterior estimates. Consequences of using imperfect tests should be accounted for at the
267 analysis stage as well as the planning stage of the estimation process.

268

269 **Conclusions**

270 Controversies between the two approaches are more a philosophical issue than a
271 practical issue. Although they originate from different statistical philosophies, Bayesian and
272 frequentist approaches are two methodological options to deal with test performance and true
273 prevalence estimation issues. While frequentists concentrate only on likelihood-based
274 estimation, Bayesians use the likelihood and prior information for estimation. Both
275 approaches proposed solutions to address challenges related to estimation of test performance
276 and true prevalence taking into account field conditions. Whatever the approach, one should
277 ensure that appropriate assumptions related to the application of a given approach hold.

278

279 **Conflict of interest statement**

280 None of the authors of this paper has a financial or personal relationship with other
281 people or organisations that could inappropriately influence or bias the content of the paper.

282

283 **Acknowledgements**

284 The authors would like to thank the Institute of Tropical Medicine of Antwerp and the
285 University of Liège, Belgium, for academic support.

286

287 **References**

- 288 Berkvens, D., Speybroeck, N., Praet, N., Adel, A., Lesaffre, E., 2006. Estimating disease
289 prevalence in a Bayesian framework using probabilistic constraints. *Epidemiology*
290 17, 145-153.
- 291
- 292 Berkvens, D.L., Speybroeck, N., Lesaffre, E., Saegerman, C., 2003. Comments on “Pouillot,
293 R., Gerbier, G., Gardner, I.A., 2002. “TAGS”, a program for the evaluation of test
294 accuracy in the absence of a gold standard. *Preventive Veterinary Medicine* 53, 67-
295 81”. *Preventive Veterinary Medicine* 59, 181-183.
- 296
- 297 Black, M.A., Craig, B.A., 2002. Estimating disease prevalence in the absence of a gold
298 standard. *Statistics in Medicine* 21, 2653-2669.
- 299
- 300 Bland, J.M., Altman, D.G., 2002. Statistics notes: Validating scales and indexes. *British*
301 *Medical Journal* 324, 606-607.

302
303 Branscum, A.J., Gardner, I.A., Johnson, W.O., 2005. Estimation of diagnostic-test sensitivity
304 and specificity through Bayesian modelling. Preventive Veterinary Medicine 68,
305 145-163.
306
307 Cowling, D.W., Gardner, I.A., Johnson, W.O., 1999. Comparison of methods for estimating
308 individual-level prevalence based on pooled samples. Preventive Veterinary
309 Medicine 39, 211-225.
310
311 Dendukuri, N., Bélisle, P., Joseph, L., 2010. Bayesian sample size for diagnostic test studies
312 in the absence of a gold standard: Comparing identifiable with non-identifiable
313 models. Statistics in Medicine 29, 2688-2697.
314
315 Dendukuri, N., Joseph, L., 2001. Bayesian approaches to modeling the conditional
316 dependence between multiple diagnostic tests. Biometrics 57, 158-167.
317
318 Dohoo, I., Martin, W., Stryhn, H., 2003. Veterinary Epidemiologic Research. AVC,
319 Charlottetown, Prince Edward Island, Canada, pp. 85-120.
320
321 Dunson, D.B., 2001. Commentary: Practical advantages of Bayesian analysis of
322 epidemiologic data. American Journal of Epidemiology 12, 1222-1226.
323
324 EnØe, C., Georgiadis, M.P., Johnson, W.O., 2000. Estimation of sensitivity and specificity of
325 diagnostic tests and disease prevalence when the true disease state is unknown.
326 Preventive Veterinary Medicine 45, 61-81.
327
328 European Food Safety Authority (EFSA), 2009. Scientific Opinion of the Panel on Animal
329 Health and Welfare (Question No EFSA-Q-2008-665), adopted on 5 June 2009.
330 Porcine brucellosis (*Brucella suis*). EFSA Journal 1144, 1-112.
331
332 Gardner, I.A., 2002. The utility of Bayes theorem and Bayesian inference in veterinary
333 clinical practice and research. Australian Veterinary Journal 80, 758-761.
334
335 Gardner, I.A., Stryhn, H., Lind, P., Collins, M.T., 2000. Conditional dependence between
336 tests affects the diagnosis and surveillance of animal diseases. Preventive Veterinary
337 Medicine 45, 107-122.
338
339 Gart, J.J., Buck, A.A., 1966. Comparison of a screening test and a reference test in
340 epidemiologic studies. II. A probabilistic model for the comparison of diagnostic
341 tests. American Journal of Epidemiology 83, 593-602.
342
343 Gelman, A., Carlin, J.B., Stern, H.S., Rubin, D.B., 2004. Bayesian data analysis. Chapman &
344 Hall/CRC, London, UK, 696 pp.
345
346 Georgiadis, M. P., Johnson, W. O., Gardner, I. A. and R. Singh, R., 2003. Correlation-
347 adjusted estimation of sensitivity and specificity of two diagnostic tests. Journal of
348 the Royal Statistical Society Series C 52, 63-76.
349
350 Godfroid, J., Nielsen, K., Saegerman, C., 2010. Diagnosis of brucellosis in livestock and
351 wildlife. Croatian Medical Journal 51, 296-305.

352
353 Greiner, M., Gardner, I.A., 2000. Application of diagnostic tests in veterinary epidemiologic
354 studies. *Preventive Veterinary Medicine* 45, 43-59.
355
356 Hui, S.L., Walter, S.D., 1980. Estimating the error rates of diagnostic tests. *Biometrics* 36,
357 167-171.
358
359 Hui, S.L., Zhou, X.H., 1998. Evaluation of diagnostic tests without gold standards. *Statistical*
360 *Methods in Medical Research* 7, 354-370.
361
362 Ihorst, G., Forster, J., Petersen, G., Werchau, H., Rohwedder, A., Schumacher, M., 2007. The
363 use of imperfect diagnostic tests had an impact on prevalence estimation. *Journal of*
364 *Clinical Epidemiology* 60, 902-910.
365
366 Irwig, L., Macaskill, P., Glasziou, P., Fahey, M., 1995. Meta-analytic methods for diagnostic
367 test accuracy. *Journal of Clinical Epidemiology* 48, 119-130.
368
369 Johnson, W.O., Gastwirth, J.L., Pearson, L.M., 2001. Screening without a ‘‘gold standard’’:
370 the Hui-Walter paradigm revisited. *American Journal of Epidemiology* 153, 921-924.
371
372 Jones, G., Johnson, W.O., Hanson, T.E., Christensen, R., 2010. Identifiability of models for
373 multiple diagnostic testing in the absence of a gold standard. *Biometrics* 66, 855-863.
374
375 Joseph, L., Gyorkos, T., Coupal, L., 1995. Bayesian estimation of disease prevalence and the
376 parameters of diagnostic tests in the absence of a gold standard. *American Journal of*
377 *Epidemiology* 141, 263-272.
378
379 Lewis, F.I., Torgerson, P.R., 2012. A tutorial in estimating the prevalence of disease in
380 humans and animals in the absence of a gold standard diagnostic. *Emerging Themes*
381 *in Epidemiology* 9, 9.
382
383 Lunn, D.J., Thomas, A., Best, N., Spiegelhalter, D., 2000. WinBUGS-A Bayesian modelling
384 framework: concepts, structure, and extensibility. *Statistics and Computing* 10, 325-
385 337.
386
387 Lunn, D., Spiegelhalter, D., Thomas, A., Best, N., 2009. The BUGS project: evolution,
388 critique and future directions (with discussion). *Statistics in Medicine* 28, 3049-3082
389
390 Menten, J., Boelaert, M., Lesaffre, E., 2008. Bayesian latent class models with conditionally
391 dependent diagnostic tests: A case study. *Statistics in Medicine* 27, 4469-4488.
392
393 Messam, L.L.M., Branscum, A.J., Collins, M.T., Gardner, I.A., 2008. Frequentist and
394 Bayesian approaches to prevalence estimation using examples from Johnne’s disease.
395 *Animal Health Research Reviews/Conference of Research Workers in Animal*
396 *Diseases*, 9, 1-23.
397
398 Meyer, N., Vinzio, S., Goichot, B., 2009: La statistique Bayésienne: Une approche des
399 statistiques adaptée la clinique. *La Revue de Médecine Interne* 30, 242-249.
400

401 Nielsen, K., 2002. Diagnosis of brucellosis by serology. *Veterinary Microbiology* 90, 447-
402 459.
403

404 O'Hagan, A., 2004. Bayesian statistics: Principles and benefits. Wageningen UR Frontis
405 Series 3, 31-45. http://library.wur.nl/frontis/bayes/03_o_hagan.pdf (accessed 12
406 August 2013).
407

408 Pepe, M.S., Janes, H., 2007. Insights into latent class analysis of diagnostic test performance.
409 *Biostatistics* 8, 474-484.
410

411 Plummer, M., 2003. JAGS: A program for analysis of Bayesian graphical models using Gibbs
412 sampling. URL [http://www.ci.tuwien.ac.at/Conferences/DSC-
413 2003/Drafts/Plummer.pdf](http://www.ci.tuwien.ac.at/Conferences/DSC-2003/Drafts/Plummer.pdf)
414

415 Pouillot, R., Gerbier, G., Gardner, I. A., 2002. "TAGS", a program for the evaluation of test
416 accuracy in the absence of a gold standard. *Preventive Veterinary Medicine* 53, 67-
417 81.
418

419 Pouillot, R., 2003. Response from R. Pouillot, G. Gerbier and I.A. Gardner to D.L. Berkvens
420 et al. (2002). *Preventive Veterinary Medicine* 59, 185-187.
421

422 Praet, N., Dorny, P., Saegerman, C., Marcotty, T., Berkvens, D., 2006. Estimation de la
423 prévalence d'une maladie et des caractéristiques des tests diagnostiques par une
424 approche Bayésienne. *Epidémiologie et Santé Animale* 49, 113-130.
425

426 Qu, Y., Hagdu, A., 1998. A model for evaluating the sensitivity and specificity for correlated
427 diagnostic tests in efficacy studies with an imperfect reference test. *Journal of the
428 American Statistical Association* 93, 920-928.
429

430 Rogan, W.J., Gladen, B., 1978. Estimating prevalence from the results of a screening test.
431 *American Journal of Epidemiology* 107, 71-76.
432

433 Rutjes, A., Reitsma, J., Coomarasamy, A., Khan, K., Bossuyt, P., 2007. Evaluation of
434 diagnostic tests when there is no gold standard. A review of methods. *Health
435 Technology Assessment* 11, 1-51.
436

437 Saegerman, C., Berkvens, D., Godfroid, J., Walravens, K., 2010. Bovine brucellosis.
438 Lavoisier & Commonwealth Agricultural Bureau – International (Ed.). In: *Infectious
439 and Parasitic Diseases of Livestock*, Paris, France, pp. 971-1001.
440

441 Saegerman, C., De Waele, L., Gilson, D., Godfroid, J., Thiange, P., Michel, P., Limbourg, B.,
442 Vo, T.K.O., Limet, J., Letesson, J.J., Berkvens, D., 2004. Evaluation of three serum
443 i-ELISAs using monoclonal antibodies and protein G as peroxidase conjugate for the
444 diagnosis of bovine brucellosis. *Veterinary Microbiology* 100, 91-105.
445

446 Saegerman, C., Vo, T.K.O., De Waele, L., Gilson, D., Bastin, A., Dubray, G., Flanagan, P.,
447 Limet, J.N., Letesson, J.J., Godfroid, J., 1999. Diagnosis of bovine brucellosis by
448 skin test: Conditions for the test and evaluation of its performance. *Veterinary
449 Record* 145, 214-218.
450

451 Sanogo, M., Thys, E., Achi, Y.L., Fretin, D., Michel, P., Abatih, E., Berkvens, D., Saegerman,
452 C., 2013. Bayesian estimation of true prevalence, sensitivity and specificity of Rose
453 Bengal test and indirect ELISA for the diagnosis of bovine brucellosis. *The*
454 *Veterinary Journal* 195, 114-120.

455

456 Speybroeck, N., Devleeschauwer, B., Joseph, L., Berkvens, D., 2012a. Misclassification
457 errors in prevalence estimation: Bayesian handling with care. *International Journal of*
458 *Public Health*. 58, 791-795.

459

460 Speybroeck, N., Williams, C.J., Lafia, K.B., Devleeschauwer, B., Berkvens, D., 2012b.
461 Estimating the prevalence of infections in vector populations using pools of samples.
462 *Medical and Veterinary Entomology* 26, 361-371.

463

464 Spiegelhalter, D.J., Best, N.G., Carlin, B.P., Van Der Linde, A., 2002. Bayesian measures of
465 model complexity and fit. *Journal of the Royal Statistical Society. Series B.*
466 *Statistical Methodology* 64, 583-616.

467

468 Staquet, M., Rozenzweig, M., Lee, Y.J., Muggia, F.M., 1981. Methodology for the
469 assessment of new dichotomous diagnostic tests. *Journal of Chronic Diseases* 34,
470 599-610.

471

472 Thrusfield, M., 2005. *Veterinary Epidemiology*. Blackwell Science, Oxford, UK, pp. 303-330.

473

474 Toft, N., Jorgensen, E., Hojsgaard, S. 2005. Diagnosing diagnostic tests: Evaluating the
475 assumptions underlying the estimation of sensitivity and specificity in the absence of
476 a gold standard. *Preventive Veterinary Medicine* 68, 19-33.

477

478 Vallverdú, J., 2008. The false dilemma: Bayesian vs. Frequentist. *E-LOGOS Electronic*
479 *Journal for philosophy* 1-17.

480

481 Walter, S.D., Irwig, L.M., 1988. Estimation of test error rates, disease prevalence and relative
482 risk from misclassified data: A review. *Journal of Clinical Epidemiology* 41, 923-
483 927.

484

485 World Animal Health Organisation (OIE), 2009. Chapter 2.4.3. Bovine brucellosis. In:
486 *Manual of Diagnostic Tests and Vaccines for Terrestrial Animals*, Paris, France, pp.
487 1-35.

488 [http://www.oie.int/fileadmin/Home/eng/Health_standards/tahm/2.04.03_BOVINE_B](http://www.oie.int/fileadmin/Home/eng/Health_standards/tahm/2.04.03_BOVINE_BRUCCELL.pdf)
489 [RUCCELL.pdf](http://www.oie.int/fileadmin/Home/eng/Health_standards/tahm/2.04.03_BOVINE_BRUCCELL.pdf) (accessed 12 August 2013).

490